Allogene Therapeutics, Inc. Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent
Allogene Therapeutics, Inc. (ALLO) had Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent of $0 as of 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Notes › Compensation Related Costs
us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent · last filed 2023-11-02
- 2023-09-30: Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent $0.00.
- 2023-06-30: Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent $0.00.
- 2023-03-31: Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent $0.00.
- 2022-12-31: Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent $600.00K.
| Period end | Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent |
|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-02 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-03 |
| 2022-12-31 | $600.00K 10-Q · filed 2023-11-02 |
| 2022-09-30 | $1.10M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $1.50M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.90M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $2.50M 10-Q · filed 2022-11-02 |
| 2021-09-30 | $3.00M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $3.40M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $400.00K 10-Q · filed 2021-05-05 |
| 2020-12-31 | $1.10M 10-Q · filed 2021-11-04 |
| 2020-09-30 | $1.80M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $2.50M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $3.20M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $3.90M 10-Q · filed 2020-11-04 |
| 2019-09-30 | $4.60M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $5.40M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $6.10M 10-Q · filed 2020-05-06 |
| 2018-12-31 | $6.80M 10-K · filed 2019-03-08 |
| 2018-09-30 | $7.50M 10-Q · filed 2018-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |